CN1593451A - Externally applied medicine for promoting male erection - Google Patents
Externally applied medicine for promoting male erection Download PDFInfo
- Publication number
- CN1593451A CN1593451A CN 03159047 CN03159047A CN1593451A CN 1593451 A CN1593451 A CN 1593451A CN 03159047 CN03159047 CN 03159047 CN 03159047 A CN03159047 A CN 03159047A CN 1593451 A CN1593451 A CN 1593451A
- Authority
- CN
- China
- Prior art keywords
- medicine
- external used
- trim
- adenosine cyclophosphate
- penis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 230000001737 promoting effect Effects 0.000 title abstract 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 9
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960001789 papaverine Drugs 0.000 claims abstract description 4
- 229960003056 phentolamine mesylate Drugs 0.000 claims abstract description 4
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940083618 sodium nitroprusside Drugs 0.000 claims abstract description 3
- 210000003899 penis Anatomy 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000010521 absorption reaction Methods 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 230000002195 synergetic effect Effects 0.000 claims description 8
- 241001597008 Nomeidae Species 0.000 claims description 7
- 239000002075 main ingredient Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 210000003708 urethra Anatomy 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 4
- 229960005305 adenosine Drugs 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 229960003194 meglumine Drugs 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- YBPWNFMPWVRSOD-QDEZUTFSSA-N 5-[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-5-hydroxynonane-4,6-dione Chemical compound C(CCC)(=O)C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC=2C(N)=NC=NC1=2)O)O)(O)C(CCC)=O YBPWNFMPWVRSOD-QDEZUTFSSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 150000003835 adenosine derivatives Chemical class 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229940009662 edetate Drugs 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 230000005284 excitation Effects 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 229960001476 pentoxifylline Drugs 0.000 claims description 2
- 239000008020 pharmaceutical preservative Substances 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 229940099259 vaseline Drugs 0.000 claims description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 abstract 2
- 230000002745 absorbent Effects 0.000 abstract 1
- 239000002250 absorbent Substances 0.000 abstract 1
- 229940095074 cyclic amp Drugs 0.000 abstract 1
- 229960004559 theobromine Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 2
- 229940043234 carbomer-940 Drugs 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical class OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an externally applied medicine for promoting male erection, wherein the medicine mainly comprises cyclicamp or its medicinal derivative, embellishing articles, absorbent prepared from medicinal findings, and Phentolamine Mesylate, papaverin hydrochloride, theobromine, sodium nitroprusside can be used as synergy agent.
Description
Technical field the invention belongs to medical technical field, relates to a kind of external used medicine that can promote male penis erection.
Background technology male penis erection dysfunction (ED) is the common and multiple disease of middle-aging male, method to the erection problem treatment is a lot, oral medicine such as sldenafil (being commonly called as " viagra ") are arranged clinically, this medicine curative effect aspect treatment ED is better, but owing to be oral administration, the side effect reaction incidence rate of general is also higher, and onset is slower, need take in one hour in the sexual intercourse precontract, price is also very expensive; Another kind of Therapeutic Method is to patient's penis cavernosa injection vasodilation example hydrochloric acid papaverine, phentolamine and prostaglandin E
1To reach quick erection, though this Therapeutic Method effect is better, can causes pain, wound and be inconvenient to use to user, also may produce serious consequences such as infection, priapism and spongy body pathological changes; Also has prostaglandin E in addition by the urethra administration
1The external ointment is to restrain medicine made in U.S.A (middle mountain) company limited production by the Buddhist nun, trade name " BEFAR ", and this medicine is with prostaglandin E
1Make the emulsifiable paste shape, absorb and promote erection fast by the urethra administration, the drug use of this external is convenient, rapid-action, safety and side effect are gently little, and its shortcoming is a prostaglandin E
1Preserve at normal temperatures and can reduce drug effect, need medicine is stored in the refrigerator, preserve very inconvenient and cost an arm and a leg, limited its scope of application.
Summary of the invention the purpose of this invention is to provide a kind of externally applied transdermal that passes through safe, efficient, that preservation is convenient, moderate and absorbs the medicine that promotes erection.
For reach above-mentioned from, the present invention adopts and to adopt certain pharmaceutic adjuvant to make the cutaneous permeable agent of external adenosine cyclophosphate or its pharmaceutically useful derivant, trim, absorbs by positions such as urethra, glans penis, prepuce of penis to enter penis and reach the effect that promotes erection.
Adenosine cyclophosphate (cyclic Adenosine Monophosphate; abbreviation cAMP) claims cyclic adenosine monophosphate (cAMP) again; it is a kind of arteriectasia agent; the pharmaceutically acceptable derivant that adenosine cyclophosphate is commonly used has meglumine adenosine cycle phosphate, dibutyryl adenosine cyclophosphate etc., is usually used in the auxiliary treatment of angina pectoris and myocardial infarction clinically.The present invention adopts adenosine cyclophosphate class medicine to promote the mechanism of erecing to be as expansion penis blood vessel: adenosine cyclophosphate class medicine is after Transdermal absorption enters body of penis, make the smooth muscle relaxation of cavernous body of penis and tremulous pulse thereof, increase the penile blood flow amount and make penis hyperemia, this effect causes that simultaneously the penis angular vein is oppressed, cause the expansion of spongy body lacuna, blood remains in a standstill, thereby promotes erection and strong.
The medicine that externally applied transdermal of the present invention absorbs, its dosage form are easy to use and smear the liquid or the body of paste of absorption, comprise dosage forms such as the various water liquid of acceptable, emulsion, emulsifiable paste, gel, cream frost on the medicine.
Owing to be the pharmaceutical dosage form that externally applied transdermal absorbs, in order to guarantee the convenient use of medicament and absorbing of medicine, the present invention is except Main Ingredients and Appearance adenosine cyclophosphate or its pharmaceutically useful derivant, trim, at least also comprise in following several composition one or more, they are that excipient, Percutaneous absorption enhancer, stabilizing agent, pH value are regulated buffer agent, medicine synergetic effect additive.
Excipient is the carrier of medicine Main Ingredients and Appearance, it is the carrier material that is used for disperseing Main Ingredients and Appearance and keeps drug form, the present invention is owing to be the cutaneous permeable agent of external, but the excipient of all cutaneous permeable agents of acceptable on the drug of choice thing is for example selected one or more combinations in water, ethanol, propylene glycol, glycerol, carbomer, cellulose, gelatin, sodium polyacrylate, polyvinyl alcohol, stearic acid, tristerin, liquid paraffin, the vaseline etc. for use;
Percutaneous absorption enhancer is to promote the medicine Main Ingredients and Appearance to see through the material of skin and mucosa absorption fast, but all Percutaneous absorption enhancers of acceptable on the present invention's drug of choice thing for example select for use one or more rents in ethanol, propylene glycol, azone, ethyl oleate, oleic acid, N-methyl-ketopyrrolidine, alpha-pyrrolidone, isopropyl myristate, Borneolum Syntheticum, Mentholum, dodecyl sodium sulfate, Polyethylene Glycol, Polysorbate, the Span to close;
Stabilizing agent is to guarantee medicine stable existence, material of never degenerating, not consuming in storage life and use, can select one or more combinations in pharmaceutical preservative, the edetate for use;
It is to regulate medicine pH value scope so that medicine is preserved stingless excitation when contacting skin that pH value is regulated buffer agent, but acceptable acid on the present invention's drug of choice thing, alkali, salt are regulated buffer agent as pH value, for example can select one or more combinations in hydrochloric acid, sodium hydroxide, citrate, the phosphate for use;
The medicine synergetic effect additive is that adenosine cyclophosphate or derivatives thereof, trim are had the synergistic material of potentiation, the present invention select for use in phentolamine mesylate, papaverin hydrochloride, pentoxifylline, the sodium nitroprusside one or more the combination as the medicine synergetic effect additive.
The present invention selects appropriate pharmaceutic adjuvant for use, adenosine cyclophosphate or its pharmaceutically acceptable derivant, trim are made the cutaneous permeable agent of external, only an amount of medicament need be splashed into urethra during use or be applied on the glans penis spongy body, absorb by positions such as urethra, glans penis, prepuce of penis, reach the congested purpose of erecing of quick promotion penis, have easy to use, safe efficient, be easy to preserve the also suitable popularity consumption of price.
Specific embodiment embodiment 1: get adenosine cyclophosphate 3 grams, and propylene glycol 5 grams, azone 3 grams, dodecyl sodium sulfate 1.5 grams, distilled water and phosphate buffer are an amount of.
Preparation method: with 1.5 gram dodecyl sodium sulfates and 70 gram distilled water Hybrid Heating dissolvings, again 5 gram propylene glycol, 3 gram azones and 3 gram adenosine cyclophosphate are added mix homogeneously successively, the reuse phosphate buffer is regulated the pH value of mixed solution between 6～8, last adding distil water to 100 milliliter, mixing, the degassing, sterilization packaging get final product.Only need during use medicinal liquid to be splashed into 1～2, get final product by the urethra absorption from urethral orifice.
Embodiment 2: get meglumine adenosine cycle phosphate 6 grams, and phentolamine mesylate 2.3 grams, carbomer-940 0.8 gram, ethanol 6 grams, glycerol 5 grams, Tween-80 0.2 gram, ethyl hydroxybenzoate 0.1 gram, sodium hydrate aqueous solution and distilled water are an amount of.
Preparation method: 0.8 carbomer-940 and 0.2 gram Tween-80 are mixed with 30 ml distilled waters, an amount of sodium hydrate aqueous solution is added upward liquid, stir, again 0.1 gram ethyl hydroxybenzoate is dissolved in adding gradually behind the ethanol and stirs evenly, liquid to be mixed adds stirring and evenly mixing successively with 6 gram meglumine adenosine cycle phosphates and the appropriate Lamine of 2.3 gram methanesulfonic acid acid after stirring and being transparence, regulates pH value after 6～8, adds to 100 milliliters with distilled water, abundant mixing, the degassing, sterilization packing promptly get gelationus agent.Take a morsel during use and be applied in glans penis and the prepuce of penis place gets final product.
Claims (10)
1. promote the external used medicine of male penis erection, the Main Ingredients and Appearance that it is characterized in that medicine is adenosine cyclophosphate or its pharmaceutically useful derivant, trim.
2. external used medicine according to claim 1, it is characterized in that in the medicine except adenosine cyclophosphate or its pharmaceutically useful derivant, trim, comprise that also excipient, Percutaneous absorption enhancer, stabilizing agent, pH value regulate one or more in buffer agent, the medicine synergetic effect additive.
3. according to claim 1 and 2 described external used medicines, it is characterized in that pharmaceutical dosage form is water liquid, emulsion, emulsifiable paste, gel or cream cream.
4. according to claim 1,2 and 3 described external used medicines, it is characterized in that medicine absorbs by phallic urethra, glans penis, prepuce of penis position.
5. external used medicine according to claim 2, it is characterized in that excipient is the carrier material that is used for disperseing Main Ingredients and Appearance and keeps drug form, but the excipient of all cutaneous permeable agents of acceptable on the drug of choice thing, one or more combinations in preferred water, ethanol, propylene glycol, glycerol, carbomer, cellulose, gelatin, sodium polyacrylate, polyvinyl alcohol, stearic acid, tristerin, liquid paraffin, the vaseline.
6. external used medicine according to claim 2, it is characterized in that Percutaneous absorption enhancer is to promote the medicine Main Ingredients and Appearance to see through the material of skin and mucosa absorption fast, but all Percutaneous absorption enhancers of acceptable on the drug of choice thing, one or more combinations in preferred alcohol, propylene glycol, azone, ethyl oleate, oleic acid, N-methyl-ketopyrrolidine, alpha-pyrrolidone, isopropyl myristate, Borneolum Syntheticum, Mentholum, dodecyl sodium sulfate, Polyethylene Glycol, Polysorbate, the Span.
7. external used medicine according to claim 2 is characterized in that stabilizing agent is to guarantee medicine stable existence, material of never degenerating, not consuming in storage life and use, can select one or more combinations in pharmaceutical preservative, the edetate for use.
8. external used medicine according to claim 2, it is characterized in that it is to regulate medicine pH value scope so that medicine is preserved the material of stingless excitation when contacting skin that pH value is regulated buffer agent, select for use on the medicine acceptable acid, alkali, salt to regulate buffer agent, preferably use one or more combinations in hydrochloric acid, sodium hydroxide, citrate, the phosphate as pH value.
9. external used medicine according to claim 2, it is characterized in that the medicine synergetic effect additive is that adenosine cyclophosphate or derivatives thereof, trim are had the synergistic material of potentiation, select for use in phentolamine mesylate, papaverin hydrochloride, pentoxifylline, the sodium nitroprusside one or more the combination as the medicine synergetic effect additive.
10. according to claim 1,2,3,4,5,6,7 or 8 described external used medicines, it is characterized in that the preferred meglumine adenosine cycle phosphate of pharmaceutically acceptable derivant, trim and the dibutyryl adenosine cyclophosphate of adenosine cyclophosphate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03159047 CN1593451A (en) | 2003-09-12 | 2003-09-12 | Externally applied medicine for promoting male erection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03159047 CN1593451A (en) | 2003-09-12 | 2003-09-12 | Externally applied medicine for promoting male erection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1593451A true CN1593451A (en) | 2005-03-16 |
Family
ID=34660579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03159047 Pending CN1593451A (en) | 2003-09-12 | 2003-09-12 | Externally applied medicine for promoting male erection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1593451A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011058374A1 (en) * | 2009-11-13 | 2011-05-19 | Biocopea Limited | Drug combination with theobromine and its use in therapy |
| US8703158B2 (en) | 2009-06-16 | 2014-04-22 | Biocopea Limited | Theobromine for the treatment of cough |
| US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| CN106110409A (en) * | 2016-08-29 | 2016-11-16 | 桂林恒保健康用品有限公司 | Extend the condom of sex time |
| US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
-
2003
- 2003-09-12 CN CN 03159047 patent/CN1593451A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703158B2 (en) | 2009-06-16 | 2014-04-22 | Biocopea Limited | Theobromine for the treatment of cough |
| US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9675618B2 (en) | 2009-06-16 | 2017-06-13 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9700561B2 (en) | 2009-06-16 | 2017-07-11 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| WO2011058374A1 (en) * | 2009-11-13 | 2011-05-19 | Biocopea Limited | Drug combination with theobromine and its use in therapy |
| CN106110409A (en) * | 2016-08-29 | 2016-11-16 | 桂林恒保健康用品有限公司 | Extend the condom of sex time |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU773144B2 (en) | Drug preparations for treating sexual dysfunction | |
| Savin | Diagnosis and treatment of tinea versicolor | |
| JP2004529935A (en) | Composition comprising an antifungal agent for treating vulvar vaginitis and vaginosis | |
| NZ271567A (en) | Use of a vasodilatory compounds in medicament for modulating human sexual response | |
| US6589990B1 (en) | Methods and compositions for misoprostol compound treatment of erectile dysfunction | |
| JPH06104624B2 (en) | Transdermal agent | |
| JPH10158169A (en) | Pharmaceutical formulation containing trospium chloride, its preparation and use | |
| CN1593451A (en) | Externally applied medicine for promoting male erection | |
| CN1279915C (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)-pyrimidine for the treatment of urinary incontinence | |
| US20210322345A1 (en) | Midodrine hydrochloride oral solution and uses thereof | |
| JP2753972B2 (en) | Treatment of impotence | |
| US7074834B2 (en) | Long acting, reversible veterinary sedative and analgesic and method of use | |
| US20030138494A1 (en) | Drug preparations for treating sexual dysfunction | |
| CN114652732B (en) | Application of pulsatilla saponin B4 in preparation of medicine for treating impotence | |
| RU2198660C2 (en) | Method and composition for treating the cases of erection dysfunction of penis | |
| US6897239B1 (en) | Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women | |
| WO2001082915A2 (en) | Trans-clitoral administration of therapy | |
| CA2366903A1 (en) | Methods for modulating the human sexual response | |
| RU2336878C2 (en) | Medication for erectile disfunction treatment | |
| AU723242B2 (en) | Methods for modulating the human sexual response | |
| WO2005067928A1 (en) | Method for treating erectile dysfunction | |
| TW200526229A (en) | External preparation for treating sexual dysfunction | |
| JP2005220052A (en) | Agent for external use for treating sexual dysfunction | |
| CA2384685A1 (en) | Use dexrazoxane for treating psoriasis | |
| Peripheral | Tetrachloroethylene. Used in treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |